![Michael Lyle](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Lyle
Direttore Tecnico/Scientifico/R&S presso Welichem Biotech, Inc.
Posizioni attive di Michael Lyle
Società | Posizione | Inizio | Fine |
---|---|---|---|
Welichem Biotech, Inc.
![]() Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Direttore Tecnico/Scientifico/R&S | 01/12/2009 | - |
Storia della carriera di Michael Lyle
Formazione di Michael Lyle
Simon Fraser University | Doctorate Degree |
Statistiche
Distribuzione geografica
Canada | 3 |
Posizioni
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Welichem Biotech, Inc.
![]() Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Health Technology |
- Borsa valori
- Insiders
- Michael Lyle
- Esperienza